November 12, 2024
Psaio Therapeutics (subsidery of Myrio Therapeutics) is thrilled to announce that it has been selected as a finalist in the 2024 ANZ Advance Biotech Grant Program […]
April 8, 2024
31 May 2023, MELBOURNE, Australia – Australia’s sovereign pandemic preparedness has received a boost with Myrio Therapeutics Pty Ltd (Myrio), a privately-owned Australian biotechnology firm with a […]
April 8, 2024
Myrio Therapeutics Pty Ltd (Myrio) today announced ground-breaking findings published in the Journal Nature. The study, titled Therapeutic Targeting of Intracellular Oncoproteins with Peptide-Centric CAR T Cells, used […]
April 8, 2024
Myrio is proud to be part of the global CoVIC consortium, providing antibodies in the fight against COVID-19. The results of the consortiums work have this […]
April 8, 2024
CAR TCR Summit: Myrio Tx shares transformational approach to targeted human antibody-based therapies
Myrio Therapeutics (Myrio Tx) is driving a new frontier of antibody-based therapies as the company’s Retained DisplayTM (ReD) antibody platform offers identification of highly specific human antibodies that […]